Table 5 CVT cases after vaccination, by time since vaccine dose
Product | Days since vaccination | Rate ratio | ||
|---|---|---|---|---|
1–14 | 15–28 | 29–84 | 1–14 vs 15–84 | |
Person-fortnights exposed | ||||
Pfizer | 1,908,751 | 1,784,505 | 4,942,003 | – |
AstraZeneca | 3,154,182 | 2,698,048 | 7,390,991 | – |
Moderna | 23,578 | 17,801 | 21,013 | – |
Cases scored as primary acute | ||||
Pfizer | 2 | 1 | 0 | – |
AstraZeneca | 7 | 2 | 5 | – |
Moderna | 0 | 0 | 0 | – |
Rate (95% credible interval) primary acute per million person-fortnights | ||||
Pfizer | 1 (0.1 to 2.9) | 0.6 | 0 | 7 (0.6 to 95.8) |
AstraZeneca | 2.2 (0.9 to 4.1) | 0.7 | 0.7 | 3.2 (1.1 to 9.5) |
Moderna | 0 | 0 | 0 | – |
Cases scored as primary acute or possible | ||||
Pfizer | 2 | 3 | 1 | – |
AstraZeneca | 9 | 3 | 7 | – |
Moderna | 0 | 0 | 0 | – |
Rate (95% credible interval) primary acute or possible per million person-fortnights | ||||
Pfizer | 1 (0.1 to 2.9) | 1.7 | 0.2 | 1.8 (0.2 to 8.9) |
AstraZeneca | 2.9 (1.3 to 5) | 1.1 | 0.9 | 2.9 (1.1 to 7.2) |
Moderna | 0 | 0 | 0 | – |